Fulfillment management system for managing ATP data in a distributed supply chain environment
    91.
    发明授权
    Fulfillment management system for managing ATP data in a distributed supply chain environment 有权
    在分布式供应链环境中管理ATP数据的履行管理系统

    公开(公告)号:US07249044B2

    公开(公告)日:2007-07-24

    申请号:US09972383

    申请日:2001-10-04

    Abstract: A fulfillment management system includes a database operable to store product availability information associated with at least one product. The fulfillment management system also includes one or more processors collectively operable to receive at least one component available-to-promise (ATP) request. Each component ATP request corresponds to a particular ATP request line-item for a desired product. The one or more processors are also operable to retrieve at least a portion of the product availability information associated with the desired product from the database for each component ATP request, determine an ATP response for each component ATP request using the retrieved product availability information, generate a component quotation for each component ATP request according to the corresponding ATP response, and communicate the component quotation for consolidation with other component quotations.

    Abstract translation: 履行管理系统包括可操作以存储与至少一个产品相关联的产品可用性信息的数据库。 履行管理系统还包括一个或多个处理器,其可共同操作以接收至少一个组件可用 - 承诺(ATP)请求。 每个分量ATP请求对应于所需产品的特定ATP请求行项目。 一个或多个处理器还可操作以从每个组件ATP请求从数据库检索与期望产品相关联的产品可用性信息的至少一部分,使用检索到的产品可用性信息确定每个组件ATP请求的ATP响应,生成 根据相应的ATP响应,每个组件ATP请求的组件报价,并将组合报价与其他组件报价进行通信。

    Systematic in silico selection method for identifying drug targets in pathogens
    92.
    发明申请
    Systematic in silico selection method for identifying drug targets in pathogens 审中-公开
    用于鉴定病原体药物靶标的系统计算机选择方法

    公开(公告)号:US20070141612A1

    公开(公告)日:2007-06-21

    申请号:US11639025

    申请日:2006-12-14

    Applicant: Sanjay Kumar

    Inventor: Sanjay Kumar

    CPC classification number: G16B20/00 G16B30/00 G16B50/00

    Abstract: Methods and compositions are provided for selecting drug targets in silico, that include the following steps performed in the order presented or an alternative order of partially or entirely at the same time: (a) identifying one or more essential or functionally important sequences from a model organism using pre-existing genomic and phenotypic data; (b) comparing sequences from (a) with a DNA or peptide sequence from a pathogen to store homologous sequences; (c) comparing sequences from the pathogen with the DNA or peptide sequence from a host organism to store those sequences absent in the host organism; and (d) comparing sequences from (b) and (c) to identify shared sequences, the shared sequences being a drug target. Additionally, identified drug targets are provided.

    Abstract translation: 提供了用于选择药物靶标的方法和组合,其包括按照所列顺序进行的以下步骤或部分或完全同时的替代顺序:(a)从模型中鉴定一个或多个必需或功能重要的序列 生物体使用预先存在的基因组和表型数据; (b)将来自(a)的序列与来自病原体的DNA或肽序列进行比较以存储同源序列; (c)将来自病原体的序列与来自宿主生物体的DNA或肽序列进行比较以存储在宿主生物体中不存在的那些序列; 和(d)比较来自(b)和(c)的序列以鉴定共享序列,所述共享序列是药物靶标。 此外,还提供了确定的药物靶标。

    Modified dna cleavage enzymes and methods for use (as amended by isa)
    93.
    发明申请
    Modified dna cleavage enzymes and methods for use (as amended by isa) 有权
    修饰的dna切割酶和使用方法(由isa修改)

    公开(公告)号:US20070042379A1

    公开(公告)日:2007-02-22

    申请号:US10585964

    申请日:2004-11-22

    CPC classification number: C12N9/22

    Abstract: Compositions and methods are provided that relate to a modified DNA cleaving enzyme having at least 35% amino acid sequence identity with T7 Endo I. The modified enzyme includes two catalytic centers separated by a β-bridge where the β-bridge contains at least one mutation having an effect of altering enzyme cleavage activity compared to the unmodified enzyme. Activities associated with the modified DNA cleaving enzyme that can be modulated in different reaction conditions include at least one of: (a) non-sequence specific nicking activity; (b) cleaving the second strand of a duplex DNA at a preexisting nick site to produce a linear duplex with a single strand overhang; (c) non-sequence specific DNA cleavage; (d) cleaving DNA flanking a mismatch; and (e) cleavage at a cruciform structure in a DNA duplex.

    Abstract translation: 提供了与T7 Endo I具有至少35%氨基酸序列同一性的修饰的DNA切割酶的组合物和方法。修饰的酶包括由β桥分开的两个催化中心,其中β-桥含有至少一个突变 与未修饰的酶相比具有改变酶裂解活性的作用。 与可以在不同反应条件下调节的修饰的DNA切割酶相关的活性包括以下至少一个:(a)非序列特异性切口活性; (b)在预先存在的切口位点切割双链体DNA的第二链以产生具有单链突出端的线性双链体; (c)非序列特异性DNA切割; (d)切断位于不对称侧翼的DNA; 和(e)在DNA双链体中的十字形结构处的切割。

    Cytokine suppressive anti-inflammatory drug binding protein
    96.
    发明授权
    Cytokine suppressive anti-inflammatory drug binding protein 失效
    细胞因子抑制性抗炎药物结合蛋白

    公开(公告)号:US06350856B1

    公开(公告)日:2002-02-26

    申请号:US09047288

    申请日:1998-03-24

    Applicant: Sanjay Kumar

    Inventor: Sanjay Kumar

    CPC classification number: C07K14/705 A61K38/00 Y02A50/411

    Abstract: p38beta2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing p38beta2 polypeptides and polynucleotides in the design of protocols for the treatment of central nervous system disorder such as senile dementia of the Alzheimer's type (SDAT), multiple sclerosis, cerebral malaria, stroke, head trauma and spinal cord injury; cardiovascular diseases such as restenosis and atherosclerosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma; and other such diseases or conditions associated with dysregulated or excess cytokines such as osteporosis, sepsis due to surgical or traumatic incident, chronic renal failure, AIDs, cachexia and autoimmune conditions such as lupus erthyromatosis, host graft rejection and graft versus host disease, among others, and diagnostic assays for such conditions.

    Abstract translation: 公开了p38beta2多肽和多核苷酸以及通过重组技术产生此类多肽的方法。 还公开了在设计用于治疗中枢神经系统疾病的方案中使用p38beta2多肽和多核苷酸的方法,例如阿尔茨海默氏型(SDAT)的老年性痴呆,多发性硬化,脑疟疾,中风,头部创伤和脊髓损伤; 心血管疾病如再狭窄和动脉粥样硬化; 炎性疾病如成人呼吸系统综合症(ARDS),类风湿性关节炎,骨关节炎,炎性肠病(IBD),牛皮癣,皮炎,哮喘; 以及与失调或过量细胞因子相关的其它这样的疾病或病症,例如由于手术或创伤事件引起的异位症,败血症,慢性肾衰竭,AIDs,恶病质和自身免疫病症如狼疮性甲状腺病,宿主移植排斥和移植物抗宿主病等 ,以及这些病症的诊断测定。

    Self-testing transceiver
    97.
    发明授权
    Self-testing transceiver 失效
    自检收发器

    公开(公告)号:US5835850A

    公开(公告)日:1998-11-10

    申请号:US693685

    申请日:1996-08-12

    Applicant: Sanjay Kumar

    Inventor: Sanjay Kumar

    CPC classification number: H04B17/15 H04B17/17 H04B17/19

    Abstract: An integrated radio frequency transceiver comprising a diversity receiver and transmitter capable of performing a self test operation to determine if the receiver and transmitter paths are properly operational. The diversity receiver includes two receiver paths, a first path for receiving radio communications having a permitted bandpass, and a second receiver path for receiving radio signals from other radio port channels in use to assist in constructing its own neighbor list.

    Abstract translation: 包括分集接收机和发射机的集成射频收发机,其能够执行自检操作以确定接收机和发射机路径是否正常工作。 分集接收机包括两个接收机路径,用于接收具有允许带通的无线电通信的第一路径和用于从其他无线电端口信道接收来自辅助构建其自己的邻居列表的无线电信号的第二接收机路径。

    Systems and methods for migrating replicated virtual machine disks
    100.
    发明授权
    Systems and methods for migrating replicated virtual machine disks 有权
    用于迁移复制的虚拟机磁盘的系统和方法

    公开(公告)号:US09047108B1

    公开(公告)日:2015-06-02

    申请号:US13607463

    申请日:2012-09-07

    Abstract: A computer-implemented method for migrating replicated virtual machine disks may include 1) replicating a virtual machine disk from an initial data store at a primary site to an initial data store at a secondary site to create a replicated virtual machine disk, 2) identifying a request to migrate the virtual machine disk within the primary site, 3) pausing replication of the virtual machine disk and mirroring the virtual machine disk from the initial data store a subsequent data store at the primary site, mirroring the replicated virtual machine disk from the initial data store to a subsequent data store at the secondary site, and 4) upon mirroring, resuming replication of the virtual machine disk by replicating the virtual machine disk from the subsequent data store at the primary site to the subsequent data store at the secondary site. Various other methods, systems, and computer-readable media are also disclosed.

    Abstract translation: 用于迁移复制的虚拟机磁盘的计算机实现的方法可以包括:1)将虚拟机磁盘从主站点的初始数据存储复制到次要站点处的初始数据存储以创建复制的虚拟机磁盘,2)识别 请求迁移主站点中的虚拟机磁盘,3)暂停虚拟机磁盘的复制,并从初始数据存储虚拟机磁盘,存储主站点上的后续数据存储,从初始镜像镜像复制的虚拟机磁盘 数据存储到辅助站点处的后续数据存储,以及4)在镜像之后,通过将虚拟机磁盘从主站点处的后续数据存储复制到辅助站点处的后续数据存储来恢复虚拟机磁盘的复制。 还公开了各种其它方法,系统和计算机可读介质。

Patent Agency Ranking